R
RXRX
Recursion Pharmaceuticals, Inc.
3.255
-0.245-7.00%Opening13:25 08/24 EDT
OPEN/PREV CLOSE3.410/3.500
TODAY RANGE3.215-3.440
VOL10.66M
MARKET CAP1.74B
52 WEEK RANGE2.770-7.18
AVG VOL (3M)21.07M
% TURNOVER1.99%
TURNOVER--
P/E (TTM)-3.1352
% RANGE6.43%
EPS(TTM)-1.0382
P/E(FORWARD)-3.7136
P/B1.900
BVPS1.713
DIVIDEND--
P/S23.02
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP1.70B
SHARES OUTSTANDING535.34M
NEXT EARNINGS11/03-11/09
FREE FLOAT523.13M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Seeking Alpha·4d ago
Tempus AI Just Had Their Entire Strategy Validated By Moderna's Vaccine Advance
Seeking Alpha·4d ago
Biotechs hit a post-pandemic high after mRNA trial win for Moderna, Merck
Seeking Alpha·5d ago
Twist Bio jumps sending AI-linked peers higher after Anthropic announcement
Simply Wall St·6d ago
Recursion Pharmaceuticals (RXRX) Is Down 5.5% After Q2 Revenue Drop And Narrower Losses - What's Changed
Simply Wall St·08/15 12:25
Recursion Pharmaceuticals (RXRX) Stock Dropped, So What Is Behind The Move?
Benzinga·08/13 12:00
Jim Cramer: These Utilities Stocks Are 'Oversold,' Fastly 'Back From The Abyss'
TipRanks·08/12 12:00
Wall Street Analysts Are Neutral on Top Healthcare Picks
Seeking Alpha·08/11 16:13
Short interest heatmap: Here are the most heavily bet-against stocks
Seeking Alpha·08/10 23:22
Recursion Pharmaceuticals: I'm Still Bearish Despite Recent Genentech News
Simply Wall St·08/10 10:42
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Analysts Just Trimmed Their Revenue Forecasts By 19%
Simply Wall St·08/09 09:31
Recursion Pharmaceuticals (RXRX) Is Up 7.3% After Mixed Q2 Results With Narrower Net Loss
Same Industry
Name/Symbol
Change%
Price